Research Interests
Animal Cell and Molecular Biology Biochemistry & Molecular Biology Bioinformatics Bioinformatics Software Cardiovascular System & Hematology Genomics Molecular Medicine Molecular Targets Oncology and Carcinogenesis Cancer Biology and Clinical Oncology Translational Health Outcomes Machine learning Artificial IntelligenceAPrf Chung Hoow Kok
Centre for Cancer Biology
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
A/Prof Chung Hoow Kok PhDA/Prof Kok is a highly experienced cancer biology, bioinformatics and artificial intelligence expert with over 10 years of experience in the field of hematological malignancies. He holds a Ph.D. in Medicine specialized in bioinformatics and cancer biology from University of Adelaide and has published numerous research papers in leading scientific journals. As a data scientist and bioinformatician, he has strong expertise on the cancer bioinformatics, predictive analytics, and artificial intelligence in cancer. His recent focus on personalised cancer medicine and bioinformatics, especially in the performance, integration, and interpretation of multi-omics of varying sizes and complexity, allowed him to establish many successful research projects bridging the divide between biology and bioinformatics with clinical significance, both nationally and internationally. Furthermore, his academic research expertise is further recognised through significant and consistent publication track record. A/Prof Kok has made significant contributions to the understanding of these diseases. He has also demonstrated expertise in machine learning and artificial intelligence, and has applied these techniques to predict treatment response and identify novel therapeutic targets. A/Prof Kok is dedicated to advancing the field of bioinformatics and artificial intelligence in hematological malignancies.
| Date | Position | Institution name |
|---|---|---|
| 2024 - ongoing | Head of data and bioinformatics innovation | South Australia Pathology |
| 2023 - ongoing | Affiliate Associate Professor | University of Adelaide, Adelaide |
| 2021 - 2023 | Head of clinical data science (MDS/AML research) | SAHMRI |
| 2018 - 2023 | Senior Bioinformatician (CML research) | SAHMRI |
| Language | Competency |
|---|---|
| Chinese (Cantonese) | Can speak and understand spoken |
| Chinese (Mandarin) | Can speak and understand spoken |
| English | Can read, write, speak, understand spoken and peer review |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2010 | University of Adelaide | Australia | PhD (Medicine) |
| Year | Citation |
|---|---|
| 2024 | Pagani, I. S., Krishnan, V., Ouyang, J., Kok, C. H., Chen, B., Page, E. C., . . . Ross, D. M. (2024). Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity. In BLOOD Vol. 144 (pp. 2715-2716). ELSEVIER. DOI |
| 2024 | Spooner, M., Yu, J., Wiseman, T., Toop, C., Khanna, S., Kok, C. H., & Hiwase, D. (2024). Extended Rhesus and Kell Phenotype-Matched Red Blood Cell (RBC) Transfusions Reduce RBC Alloimmunization and RBC Transfusion Burden in Patients with Myeloid Neoplasm. In BLOOD Vol. 144 (pp. 5593-5594). ELSEVIER. DOI |
| 2024 | Shah, M., Hung, K., Baranwal, A., Price, Z., Al-Kali, A., Toop, C., . . . Hiwase, D. (2024). The 66th ASH Annual Meeting Abstract Abstracts. In BLOOD Vol. 144 (pp. 3214). ELSEVIER. |
| 2024 | Wiseman, T., Spooner, M., Khanna, S., Hung, K., Toop, C., Singhal, D., . . . Hiwase, D. (2024). Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic. In BLOOD Vol. 144 (pp. 3209). ELSEVIER. DOI WoS1 |
| 2024 | Hung, K., Al-Kali, A., Toop, C., Patnaik, M. M., Price, Z., Kourelis, T., . . . Shah, M. (2024). <i>TP53</i>-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors. In BLOOD Vol. 144 (pp. 4594-4595). FL, Orlando: ELSEVIER. DOI WoS2 |
| 2024 | Branford, S., Fernandes, A., Wadham, C., Maqsood, M., Shahrin, N. H., Ross, D. M., . . . Shanmuganathan, N. (2024). Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure. In BLOOD Vol. 144 (pp. 996-997). FL, Orlando: ELSEVIER. DOI |
| 2024 | Shanmuganathan, N., Wadham, C., Yeung, D., Shahrin, N. H., Fernandes, A., Maqsood, M., . . . Branford, S. (2024). Strong Association between Cancer Gene Variants at Diagnosis, Especially<i> ASXL1,</i> and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors. In BLOOD Vol. 144 (pp. 992). FL, Orlando: ELSEVIER. DOI WoS5 |
| 2024 | Hiwase, D., Price, Z., Kok, C. H., Kutyna, M., Singhal, D., Shanmuganathan, N., . . . Scott, H. S. (2024). Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure. In BLOOD Vol. 144 (pp. 4596-4597). FL, Orlando: ELSEVIER. DOI |
| 2023 | Branford, S., Wadham, C., Shanmuganathan, N., Fernandes, A., Shahrin, N. H., Feng, J., . . . Hughes, T. P. (2023). Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML. In BLOOD Vol. 142 (pp. 5 pages). CA, San Diego: ELSEVIER. DOI WoS5 |
| 2023 | Hong, L. E., Kok, C. H., Kutyna, M., Li, J. J., Chhetri, R., Ross, D. M., . . . Hiwase, D. (2023). High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: ELSEVIER. DOI |
| 2023 | Hiwase, D., Baranwal, A., Shah, S., Kutyna, M., Hahn, C. N., Abdelmajid, M., . . . Shah, M. V. (2023). Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: ELSEVIER. DOI |
| 2023 | Shah, M. V., Kutyna, M., Shah, S., Tran, E. N. H., Baranwal, A., Ladon, D., . . . Hiwase, D. (2023). Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: ELSEVIER. DOI WoS4 |
| 2022 | Radich, J. P., Kok, C. H., Chelysheva, E. Y., Cortes, J. E., Jiang, Q., Mauro, M., . . . Hughes, T. (2022). A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income. In BLOOD Vol. 140 (pp. 9617-9619). LA, New Orleans: ELSEVIER. DOI WoS2 |
| 2022 | Branford, S., Shanmuganathan, N., Wadham, C., Shahrin, N. H., Fernandes, A., Feng, J., . . . Hughes, T. (2022). Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML. In BLOOD Vol. 140 (pp. 3916-3917). LA, New Orleans: ELSEVIER. DOI WoS1 |
| 2022 | Kok, C. H., Tran, E. N. H., Ladon, D., Chhetri, R., Baranwal, A., Sharplin, K. M., . . . Hiwase, D. (2022). Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 140 (pp. 6962-6963). LA, New Orleans: ELSEVIER. DOI |
| 2021 | Kutyna, M., Kok, C. H., Wee, L. Y., Paton, S., Chhetri, R., Thomas, D., . . . Hiwase, D. (2021). BONE MARROW MICROENVIRONMENT IN THERAPY-RELATED MYELOID NEOPLASMS IS DISTINCT FROM OTHER MYELOID NEOPLASMS, PROBABLY DRIVEN BY PRIOR CYTOTOXIC THERAPY. In LEUKEMIA RESEARCH Vol. 108 (pp. S18-S19). PERGAMON-ELSEVIER SCIENCE LTD. |
| 2021 | Pagnano, K. B., Kok, C. H., Mauro, M. J., Cortes, J. E., Evans, N., Jiang, Q., . . . Hughes, T. P. (2021). COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER. DOI WoS3 |
| 2021 | Kutyna, M. M., Kok, C. H., Paton, S., Cakouros, D., Arthur, A., Hughes, T. P., . . . Hiwase, D. (2021). Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2021 | Lu, L., Dang, P., HoowKok, C., Saunders, V. A., Branford, S., P.Hughes, T., & TYeung, D. (2021). Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER. DOI WoS1 |
| 2019 | Kok, C. H., Liu, L., Yeung, D. T., Saunders, V. A., Dang, P., & Hughes, T. P. (2019). A Combination of <i>CD302</i> gene Expression and 3-Months <i>BCR</i>-<i>ABL1 Level</i> Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2016 | Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). <i>In Vitro</i> Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2016 | Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2016 | Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group. |
| 2015 | Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2014 | Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | Watkins, D. B., Kok, C. H., Hughes, T. P., Slader, C., D'Andrea, R., & White, D. L. (2011). Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. In BLOOD Vol. 118 (pp. 727). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | D'Andrea, R. J., Perugini, M., Kok, C. H., Salerno, D., Danner, S., Bardy, P. G., . . . Lewis, I. D. (2011). Methylation of a Single CpG in the <i>GADD45A</i> Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia. In BLOOD Vol. 118 (pp. 1511). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2010 | Powell, J. A., Thomas, D., Barry, E. F., Kok, C. H., Ma, L. Y., To, L. B., . . . Guthridge, M. A. (2010). TARGETING CELL SURVIVAL PATHWAYS IN ACUTE MYELOID LEUKEMIA. In EXPERIMENTAL HEMATOLOGY Vol. 38 (pp. S60). Melbourne, AUSTRALIA: ELSEVIER SCIENCE INC. |
| 2005 | Wilkinson, C., Brown, A., Kok, C., Solomon, P., Goodall, G., Gonda, T., & D'Andrea, M. (2005). Expression profiling of a myeloid cell line model to identify novel transcription factors influencing myeloid cell differentiation proliferation and leukaemia. In Proceedings of 5th Australian Microarray Conference 2005 (pp. unknown). Australia: Unknown. |
| Year | Citation |
|---|---|
| 2022 | Shah, M. V., Hahn, C. N., Chhetri, R., Tran, E. N. H., & Hiwase, D. (2022). Integrated personalized prediction model identifies a subgroup of wild-type tp53therapy-related myeloid neoplasm patients with poor outcome. Poster session presented at the meeting of Blood. US: American Society of Hematology. DOI |
| 2018 | Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . . White, D. L. (2018). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of 23rd Congress of European Hematology Association. Stockholm, Sweden. |
| 2018 | Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . . . White, D. L. (2018). Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing. Poster session presented at the meeting of NDLR. |
| 2018 | Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR. |
| 2018 | Lu, L., Kok, C., Saunders, V., Nievergall, E., White, D. L., & Hughes, T. P. (2018). TGF-α predicts TKI treated CML patients who fail to achieve early molecular response. Poster session presented at the meeting of NDLR. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster, Adelaide Protein Group (APG) Student Awards. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Oral, Australian Society for Medical Research (ASMR) SA Meeting. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and Characterisation of Ruxolitinib Resistant Mutations in JAK2-rearranged B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster, Australasian Genomic Technologies Association (AGTA) Annual Conference. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at the meeting of Poster, Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster, South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster, European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium. |
| 2017 | McClure, B. J., Heatley, S. L., Kok, C., Sadras, T., An, J., Quek, K., . . . White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult pre-B-ALL patients. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Heatley, S. L., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk-Adapted Treatment. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Poster session presented at the meeting of Abstracts of the 57th Annual Meeting of the American Society of Hematology, as published in Blood. Orlando, FL: American Society of Hematology. DOI WoS2 |
| 2017 | Downes, C. E., McClure, B. M., Heatley, S. H., Sadras, T. S., Hughes, T. H., Kok, C. K., . . . White, D. W. (2017). Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster, Australian Society for Medical Research (ASMR) SA Meeting. Adelaide. |
| 2016 | Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I., . . . White, D. (2016). HIGH GENE EXPRESSION OF HIST1H2AG AND HIST1H4A REDUCES IMATINIB UPTAKE INTO CML CELLS AND PREDICTS POOR RESPONSE TO FRONTLINE IMATINIB THERAPY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2016 | Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I. S., . . . White, D. L. (2016). High Gene Expression of hist1h2ag and hist1h4a Reduces Imatinib Uptake into CML Cells and Predicts Poor Response to Frontline Imatinib Therapy. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Heatley, S., Sadras, T., McClure, B., Kok, C. H., Dang, P., Nievergall, E., . . . White, D. L. (2016). The Incidence of Ph-like Acute Lymphoblastic Leukaemia (ALL) Increases with Age and is Characterised by Poor Outcome. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Van der Hoek, M., Heatley, S., . . . Ross, D. (2016). Mitochondrial DNA Mutations at Diagnosis are Linked to Response in TKI treated Chronic Myeloid Leukaemia Patients. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T., & White, D. L. (2016). Modelling Ponatinib Resistance In BCR-ABL1+ Cell Lines: Implications For Ponatinib Therapy. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Heatley, S., Sadras, T., kok, C., Venn, N., Revesz, T., Osborn, M., . . . White, D. L. (2016). Australian Children with Ph-like ALL enrolled to ANZCHOG ALL8 had a high prevalence of relapse despite risk adapted treatment. Poster session presented at the meeting of CLS SCIENTIFIC PROGRAMME, Refractory Leukemia and Miscellaneous. Athens. |
| 2016 | Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . . . White, D. L. (2016). A nine-gene signature defines 2 groups of CRLF2 rearranged B-ALL patients with distinctive genetic features. Poster session presented at the meeting of .. Athens. |
| 2016 | Pagani, I. S., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . Ross, D. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia. Poster session presented at the meeting of .. Barcelona, Spain. |
| 2016 | Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . . . White, D. L. (2016). CRLF2 rearranged B-ALL cases with a Ph-like gene signature are enriched for JAK2 mutations. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). Modelling ponatinib resistance in BCR-ABL1+ cell lines: implications for ponatinib therapy. Poster session presented at the meeting of New Directions in Leukaemia Research 2016. Noosa, QLD. |
| 2016 | McClure, B., Heatley, S., Sadras, T., Nievergall, E., Kok, C., Dang, P., . . . White, D. L. (2016). Identification of a significantly high prevalence of relapse in Australian children with Ph-like ALL. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Pagani, I., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . White, D. L. (2016). Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukemic clone?. Poster session presented at the meeting of .. Noosa, QLD. |
| 2015 | Wang, J., Kok, C. H., Leclercq, T. M., Saunders, V. A., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2015). High peroxisome proliferator-activated receptor-gamma (PPAR gamma le) transcriptional activity reduces active influx of imatinib and kinase inhibition in CML cells. Poster session presented at the meeting of Blood. US: American Society of Hematology. |
| 2014 | Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. DOI WoS1 |
| 2014 | Maung, K. Z., Gray, J. X., Leo, P. J., Bassal, M., Brown, A. L., Bray, S. C., . . . Gonda, T. J. (2014). Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2014 | Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T. P., & White, D. L. (2014). Modeling Ponatinib Resistance in <i>BCR-ABL1</i>+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naive Patients. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY. |
| 2013 | Wang, J., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2013). Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. DOI |
| 2012 | D'Andrea, R. J., Perugini, M., Diakiw, S. M., Kok, C. H., Salerno, D., Cummings, N., . . . Lewis, I. D. (2012). Methylation of the Proximal Promoter of <i>GADD45A</i> Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI |
| 2012 | Watkins, D. B., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2012). Global DNA methylation analysis identifies key pathway differences between poor (low OCT-1 activity) and standard risk CP-CML patients at diagnosis. Poster session presented at the meeting of “Abstracts of the 54th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood. Atlanta, GA: America Society of Hematology. |
| 2011 | Sadras, T., Perugini, M., Ramshaw, H. S., Salerno, D. G., Kok, C. H., Lewis, I. D., . . . D'Andrea, R. J. (2011). IL-3 REGULATES B-CATENIN IN MYELOID CELLS AND ENFORCED EXPRESSION OF B-CATENIN REDUCES THE DEPENDENCY ON IL-3 FOR SURVIVAL. Poster session presented at the meeting of EXPERIMENTAL HEMATOLOGY. ELSEVIER SCIENCE INC. |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2025 | Principal Supervisor | Identification of germline genomic copy number variations in familial leukemia using next generation sequencing | Doctor of Philosophy | Doctorate | Full Time | Mr Yiming Jiang |
| 2025 | Principal Supervisor | Identification of germline genomic copy number variations in familial leukemia using next generation sequencing | Doctor of Philosophy | Doctorate | Full Time | Mr Yiming Jiang |
| 2022 | Co-Supervisor | - | Doctor of Philosophy | Doctorate | Full Time | Ms Muneeza Maqsood |
Connect With Me
External Profiles
